During a recent visit to KSB Biotech in China, IDL Diagnostics and its German partner concile explored potential additions to Concile Global’s international point-of-care testing portfolio.
Discussions focused on biomarkers compatible with the reader platforms already used for UBC® Rapid, potentially enabling a broader offering through shared instruments and distribution channels. Opportunities remain under evaluation.
IDL Diagnostics recently met with CLIA partner Zecen, and its Chinese distributors Vastec, Sysmex and Fosun, to discuss market opportunities and portfolio development. Discussions highlighted China’s national pricing-code framework, expected to be implemented by the...
CEO Gustav Sten and CFO Ellen Dittberner present the company’s Q3’26 results – November 5, 2026
Last week, IDL Diagnostics participated in Urology Week 2026 in Växjö. The event brought together professionals from across the field of urology and offered a valuable opportunity to engage in discussions about current research, clinical perspectives and ongoing...
